Corcept Therapeutics Inc Stock Price, News & Analysis

Corcept Therapeutics (CORT) reported Q2 2022 revenue of $103.4 million, an increase from $91.6 million in Q2 2021. The company reiterated its 2022 revenue guidance of $400 - $430 million. Net income for the quarter was $27.4 million or $0.24 per share, up from $0.21 in the prior year. Cash and investments rose to $382.0 million, reflecting solid growth. Corcept continues to advance clinical trials for relacorilant, addressing conditions such as platinum-resistant ovarian cancer and Cushing’s syndrome, with completion of multiple Phase 2 trials expected by year-end.

Corcept Therapeutics (NASDAQ: CORT) will report its second quarter financial results and provide a corporate update on August 3, 2022, with a conference call at 5:00 p.m. ET. The company has a robust portfolio of proprietary compounds targeting cortisol modulation for severe disorders, including Cushing’s syndrome and cancers. They are also working on clinical trials for other conditions. The call will be accessible through registration, and a replay will be available on their website.

Corcept Therapeutics announced the initiation of the ROSELLA Phase 3 trial for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer. The previous Phase 2 trial demonstrated improved progression-free survival, duration of response, and overall survival without increasing side effects. The pivotal trial aims to enroll 360 women and is critical as limited treatment options exist for this patient population. Success could establish relacorilant as a new standard of care.

Corcept Therapeutics has announced the initiation of a registrational Phase 3 trial for relacorilant plus nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer. The decision follows a successful Phase 2 study showing significant improvements in progression-free survival, duration of response, and overall survival without added side effects. The new trial, named ROSELLA, aims to enroll 360 women and is designed to replicate the positive outcomes observed previously. Results will be presented at the ASCO Annual Meeting.

Corcept Therapeutics (NASDAQ: CORT) reported Q1 2022 results with revenue of $93.7 million, up from $79.4 million in Q1 2021. The diluted net income per share rose to $0.20, compared to $0.18 a year earlier. The company reiterated its 2022 revenue guidance of $400 - $430 million. Cash and investments increased to $368.1 million as of March 31, 2022. Corcept is advancing multiple clinical trials, notably in platinum-resistant ovarian cancer and Cushing’s syndrome, with a pivotal trial expected soon. A conference call was held on May 5, 2022.

Corcept Therapeutics (NASDAQ: CORT) will report its first quarter financial results on May 5, 2022, followed by a corporate update and a conference call at 5:00 p.m. ET. The company specializes in cortisol modulation and has developed a portfolio of proprietary compounds for serious disorders, including Cushing's syndrome. Korlym®, its flagship drug, was the first FDA-approved treatment for Cushing's. Details for joining the call are provided, ensuring access for investors and stakeholders.

Corcept Therapeutics announced key appointments in leadership roles to enhance commercial and development initiatives. Daniel Einhorn was appointed Vice President of Endocrine Strategy, bringing over 30 years of experience in clinical endocrinology. Amiel Balagtas joins as Vice President of Development Operations, with a strong background from Gilead Sciences. Lyndah Dreiling is the new Vice President of Global Oncology Development, adding extensive experience in drug development. These leadership changes aim to strengthen Corcept's position in treating severe disorders through innovative drug solutions.

Corcept Therapeutics (NASDAQ: CORT) has announced the completion of enrollment for its GRATITUDE trial, investigating miricorilant as a treatment for weight gain induced by antipsychotics in patients with schizophrenia or bipolar disorder. The trial, which includes 600 mg of miricorilant or placebo daily over 12 weeks, aims to evaluate weight reduction and safety. Data is expected in Q4 2022. Additionally, the company is conducting a second trial, GRATITUDE II, for long-term antipsychotic-induced weight gain, with results also due in Q4. Both studies are vital for addressing metabolic side effects of antipsychotics.

Corcept Therapeutics (CORT) announced promising Phase 2 trial results for relacorilant combined with nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer. The treatment showed a 33% overall reduction in risk of death compared to nab-paclitaxel alone (hazard ratio: 0.67; p-value: 0.066). When excluding patients with severe prior therapies, the benefit increased to 48% (hazard ratio: 0.52; p-value: 0.010). The company plans to initiate a Phase 3 trial in Q2 2022 and aims to establish relacorilant as a new standard of care for this difficult-to-treat population.